Delays in cancer treatment authorization often impede optimal patient care. In this retrospective assessment of payment rates, the Dana-Farber Cancer Institute explores payer approval decisions for on-pathway treatments.
Delays in cancer treatment authorization often impede optimal patient care. In this retrospective assessment of payment rates, the Dana-Farber Cancer Institute explores payer approval decisions for on-pathway treatments.
Delays in cancer treatment...